STOCKS TELEGRAPH

Tag: ZOM Stock

  • 2021 Revenue & Gross Margin Updates: Zomedica Corp. (ZOM) stock Rebounds After hours

    2021 Revenue & Gross Margin Updates: Zomedica Corp. (ZOM) stock Rebounds After hours

    On February 25, Zomedica Corp. (ZOM) provided its Q4 and fiscal 2021 revenue and gross margin update. Consequently, the stock rebounded in the after-hours on Friday.

    During the regular trading session, the stock suffered a loss of 3.32% at 37.86 million shares. ZOM closed the session at $0.35 per share after fluctuating between $0.34 and $0.38 during the session. Following the announcement, the stock made a comeback in the after-hours to gain a good 15.92%. Hence, ZOM was trading at a value of $0.40 per share at an after-hours volume of 14.48 million shares, on Friday.

    The veterinary health company, Zomedica Corp. was founded in 2013. Currently, its 979.89 million outstanding shares trade at a market capitalization of $342.18 million. ZOM stock has added a value of 13.93% year to date, while it subtracted a huge 81.33% last year.

    ZOM’s Revenue & Gross Margin

    For the fourth quarter and fiscal 2021, the company reported total revenue of $4.1 million, against $0 in the same periods of the previous year. Moreover, ZOM had a gross margin of 73.9% and cash and cash equivalents were $195 million at the end of 2021.

    In Q4, PluseVet’s revenue increased by 66% YOY to $4.0 million, against $2.4 million in the year-ago period.

    Furthermore, the TRUFORMA® product revenue increased by 22$ to $73,000 in Q4 2021, against $22,500 in the previous quarter.

    The company will release its complete Q4 and fiscal 2021 results on March 1, 2022. Additionally, the company’s progress and future outlook will be discussed during its Q1 Virtual Investor Summit on March 8, 2022.

    Management Team Additions

    Recently, the company announced multiple new additions to its management team, including:

    Firstly, on February 15, ZOM announced the appointment of Adrian Lock, Vice President, and General Manager, for leading its sales organization. Mr. Lock is the founding CEO of PluseVet and has been directing the company’s sales activities for over 10 years.

    Secondly, on February 07, with more than 25 years of experience, Nicole Westfall joined ZOM as the Vice President, Marketing.

    Thirdly, on January 25, with over 30 years of experience, Kristin Domanski was appointed as the Vice President, Human Resources of the company.

    And, on January 2, Tony Blair was appointed as the Executive Vice President, Operations, who comes with over 35 years of experience.

    In addition, Mr. Evan Saint-Peter has been promoted to the role of Vice President, Technology Innovation.

  • Zomedica Corp. (ZOM) Stock Gaining Momentum in Premarket. Here’s What’s Happening.

    Zomedica Corp. (ZOM) Stock Gaining Momentum in Premarket. Here’s What’s Happening.

    Zomedica Corp. (ZOM) is veterinary wellness and health-based company. It offers diagnostics and treatments for pets by fixing their unmet medical needs. The company’s product line includes novel diagnostics and devices, which are intended to improve the health of patients.

    The price of ZOM stock during the regular trading on February 17, 2022, was $0.40 with a gain of 5.26%. At last check in the premarket on February 18, 2022, the stock was further up by 7.17%.

    ZOM: Events and Happenings

    ZOM updated about its Executive management’s participation at the following events.

    • Midwest Veterinary Conference held on February 17-19, 2022.
    • Music City Veterinary Conference being held on February 18-20, 2022, and
    • Q4 Earnings Release Conference is being held on February 25, 2022.

    On February 15, 2022, ZOM updated that the Company’s sales organization is now led by Adrian Lock. He was Vice President and General Manager of the company and will lead sales management and professional service veterinarians. On January 27, 2022, ZOM provided an update on its business and marketing activities in Q1 2022. On December 15, 2021, ZOM announced its Executive management’s presence at the Virtual H.C. Wainwright BioConnect 2022 Conference held on 10-13, 2022.

    ZOM: Key Financials

    On November 12, 2021, ZOM released its financial results for the third fiscal quarter 2021 ended September 30, 2021. Some of the key updates are mentioned below.

    Revenue

    Net revenue in Q3 2021 was $22.5 thousand compared to no revenue in the same quarter of 2020. The company reported an increase in its revenue over the year.

    EPS

    Basic and diluted net loss per share in Q3 2021 was $6.34 million or $0.01 against $4.97 million or $0.01 in the same quarter of 2020. The net loss of the company increased over the yearly period.

    On October 01, 2021, ZOM was informed about the acquisition of Pulse Veterinary Technologies for $70.9 million. Pulsevet is a leading electro-hydraulic shock wave technology for the treatment of a wide range of veterinary patients.

    Conclusion

    ZOM stock down-performed by 81% in the past year as the economic turmoil surrounded the international businesses due to pandemics. The current stock market gain by the company is likely the result of its announcement related to attendance of veterinary conferences and earnings release calls.

  • What Is Raising The ZOM Stock Up Pre Market?

    What Is Raising The ZOM Stock Up Pre Market?

    The shares of Zomedica Corp. (ZOM) have increased 4.51% to $0.7420 in premarket trading as of last check. Zomedica stock ended Thursday’s session down -3.43% at $0.71. There were 24.42 million shares traded which was below the average daily volume of 34.07 million shares during the past 50 days. Zomedica has a current market capitalization of $721.74 million, and its outstanding shares amount to 977.81 million. After providing an update on the company’s performance, ZOM stock has been rising.

    ZOM has updated what?

    Zomedica is a veterinary health company based in Ann Arbor, Michigan, that focuses on meeting the unmet needs of clinical veterinarians. ZOM intends to offer a product portfolio that emphasizes both patient and practitioner health by developing innovative diagnostics and medical devices. Zom is committed to helping veterinarians increase productivity and increase revenue while improving the care of animals.

    The veterinary health company, Zomedica, that designs point-of-care diagnostic products for both dogs and cats, has issued the following corporate update:

    • ZOM’s flagship product, TRUFORMA, will offer five initial assays to detect adrenal and thyroid disorders, followed by several more assays that will cover numerous diseases.
    • As of now, three of ZOM’s initial tests are available.
    • Since its development partner, Qorvo Biotechnologies, is yet to complete the fT4 and ACTH assays, ZOM wants to encourage veterinarians to adopt the TRUFORMA platform in order to test it.
    • ZOM is undertaking this effort now and will continue until the summer of 2021.
    • ZOM is also actively recruiting top-level representatives, professional services veterinarians, and support staff so that it can effectively execute its instrument placement programs and prepare for a significant increase in sales once fT4 and ACTH is available for purchase.
    • ZOM plans to hire fifteen direct sales representatives by the end of 2021, as well as four veterinarians who will perform professional services, as well as inside sales representatives and customer service personnel.
    • The fT4 assay is expected to hit the market in late September or early October, followed two months later by ACTH.
    • In addition, three new tests (cPL, Cobalamin, and Folate) are under development to diagnose gastro-intestinal conditions.

    ZOM’s further efforts:

    Currently, Ziomedica (ZOM) and Qorvo are discussing when and how further assays will be developed after those already identified. It is also expected that ZOM’s TRUFORMA will be available in select markets outside the United States in 2022. Zomedica employees in Michigan have also returned to working on-premises beginning July 6, 2021.

  • Zomedica Corp. (ZOM) soared in the current session; here’s why

    Zomedica Corp. (ZOM) soared in the current session; here’s why

    In the current market, Zomedica Corp. (ZOM) stock plummeted by 0.77% to the price of $0.84 at the time of writing. ZOM stock closed its previous trading session at $0.85.

    The expansion of a direct sales team and organization for ZOM and TRUFORMA

    The ZOM stock announced on 15th April 2021 that it has planned to expand its operations of commercialization, marketing and sales of its product. Zomedica will do so by expanding the direct sales organization and at the same time shifting from its distributor-based sales effort.

    The ZOM stock wants to transition into the distributor-based sales model as quickly as possible because the anticipated disruption and changes in the current distributor has limited the ability for the company to market its products effectively. Therefore accelerating towards the direct sales organization is the immediate operative goal and transition that the company is working on.

    Initially affect the sales of TRUFORMA and other products but only for the short term; in the long term the operative process of direct sales will strengthen the development, commercialization, and sales of any future product along with TRUFORMA.

    The accelerated process of developing the direct sales team has proven effective because the company has a current sales force of eight employees as direct field sales personnel that come under two regional managers and the executive vice president of sales and chief commercial officer.

    The company believes that this direct sales force will dramatically improve the ability to serve the customers and effectively sell the products in the veterinary market based on the long-term plan. For this, the first commercial sale of the company’s product before its launch date has been a sign of high expectations of demand for TRUFORMA and Zomedica’s financial strength.

    The potential of ZOM stock’s performance and sales of TRUFORMA in 2021

    With the latest milestone in its flagship product, we need to look into the stats of the pet diagnostic market. The most significant data about the market is that 93% of the dog owners visit veterinary annually and with the average lifespan of dogs in mind, that means they will visit for 15 years give or take. Furthermore, 67% of the households keep a single pet at least and $99 billion is the amount that consumers spent on their pets in the US, 2020.

    The performance of the sales operation gives and potential market share gives investors and shareholders a positive expectation for the ZOM stock. However, there is still the volatility of the stock in the past one-year trend that needs to be heeded.

    These stats are very welcoming for Truforma and with other assays in the phase to be released soon, 2021 seems highly for ZOM stock to rise. Zomedica has also submitted an in the company’s SEC 10-K form, a bull thesis which indicates the market potential for companion animal diagnostic market forecasted to reach $2.8 billion  (a 5-year CAGR of 9.8%) by 2024. Similarly, the global veterinary immunodiagnostic market has been forecasted to reach $2.1 billion by 2022 (CAGR 9.6%) This potential is well within reach as the company keeps reaching its milestones one by one.

  • Zomedica Corp. (ZOM) stock plunged in the pre-market trading session: here’s why

    Zomedica Corp. (ZOM) stock plunged in the pre-market trading session: here’s why

    Zomedica Corp (ZOM) stock recently traded at $1.33 which is an 8.90% downward movement. The ZOM stock previously closed at $1.46. ZOM stock also plunged in the pre-market trading session by 11.28% at the time of writing.

    The recent pattern of negative movement in the ZOM stock isn’t due to any recent PR news as of April. But this stock has been known to be volatile and gives traders quick short gains or losses if they are not lucky.

    About Zomedica Corp

    Zomedica Corp (NYSE: ZOM) is a veterinary health company that creates commercial products for pets specifically cats and dogs. They focus especially on delivering and innovating products which tend to be the unmet needs of the clinical veterinarians.

    Dwelling deeper into the ZOM stock performance

    Zomedica Corp (ZOM) stock due to its volatility pattern in 2021 would suggest that it should not be kept for the long position. In the month of December 2020, the stock was worth 20-25 cents per share however it entered the year 2021 with a bounce in price up to $1.30 and didn’t stop there. It shot well over the $2 mark and up to $2.91 in February. However, the stock has jumped down from the peak-price climb and now is around $1.30-$1.35 per share.

    If you have experience with trading in for short positions and swift market timing then this stock can definitely give you a reward. For that it is also important that you understand what is the recent operational activities happening in the ZOM stock’s fundamentals;

    Zomedica has released a veterinary diagnosis-kit that has been tailor made and sold known as TRUFORMA. This was delivered on 16th March, ahead of the announced 30th March date. It is an on-site canine eACTH assay that is created for the purpose of eliminating the risk of sample transport error. Furthermore, it aids in the diagnosis of adrenal disease. To learn more, read our article covering this news by clicking here.

    What makes ZOM stock so special?

    With the latest milestone in its flagship product, we need to look into the stats of the pet diagnostic market. The most significant data about the market is that 93% of the dog owners visit veterinary annually and with the average lifespan of dog in mind, that means they will visit for 15 years give or take. Furthermore, 67% of the households keep a single pet at least and $99 billion is the amount that consumers spent on their pets in the US, 2020.

    These stats are very welcoming for Truforma and with other assays in the phase to be released soon, 2021 seems highly for ZOM stock to rise. Zomedica has also submitted an in the company’s SEC 10-K form, a bull thesis which indicates the market potential for companion animal diagnostic market forecasted to reach $2.8 billion  (a 5-year CAGR of 9.8%) by 2024. Similarly, the global veterinary immunodiagnostic market has been forecasted to reach $2.1 billion by 2022 (CAGR 9.6%) This potential is well within reach as the company keeps reaching its milestones one by one.

  • The Three Cheap Stocks to Keep in your Investment List

    The Three Cheap Stocks to Keep in your Investment List

    The global pandemic has affected many high price stocks and with much uncertainty, we have certain cheap stocks to watch for.

    Last year has been total devastation and things have turned upside down for most of the companies in the stock market. We have seen many companies whose dynamics have changed during the last years’ time. For instance, companies which totally relied upon retail store have understood the significance of online stores and are moving to e-market—now.

    In the meantime, the investor’s behavior changed due to rising uncertainty and for risk-averse investors, the cheap stocks with high potential are the best investment options. Let’s see the three cheap stocks for investment.

    Zomedica (ZOM)

    Zomedica (ZOM) is one of the most promising cheap stocks in the market. Zomedica is a development stage veterinary diagnostic and pharmaceutical company for dogs and cats. The company is well-positioned and has improved its performance during 2020 following a rise in pets’ products.

    Recently, Zomedica recorded the first veterinarian sale of TRUFORMA® and officially entered commercialization. This will help the company grow its sales and give a competitive edge in the market. It’s a long-term success story for the company and investors would be quite proud of it.

    Zomedica (ZOM) is trading on a lower side, which could be a perfect buy for investors. The future outlook seems solid. So, ZOM wouldn’t be a bad investment at all.

    Navient (NAVI)

    Navient (NAVI) provides loans to students. The company menacing time in 2020 as the borrowers disappear in quarantine. Reporting one of its worst ever, Navient saw 28.5% of its federal loan borrowers and 14.7% of its private loan borrowers hiding themselves during Q2. However, things improved with the following figures dropping to 13.8% and 3.9% on federal and private loans, respectively.

    Navient stock is trading around its new 52-week high price of $14 as the bullish sentiment continues to increase. The rising bulls are largely pushed by the anticipation of increasing recovery of the finance sector. Moreover, the company expects to see higher charge-offs during the year, jumping from 0.88% in 2020 to 3% in 2021. Overall, Navient is quite optimistic about its fortune this year, which will bring improvements in lending.

    Glu Mobile (GLUU)

    Glu Mobile (GLUU) has been performing radiantly, recently. The company was mostly driven by the announcement of EA following the all-cash buyout deal with Glu at an implied enterprise value of $2.1 billion.EA has high expectations from Glu’s rising sales and positive operating profits right away. The acquisition is expected to close in Q2 2021, based on the shareholder’s consent.

    In the fourth quarter, the company reported impressive outcomes with revenue jumping up to 25% year over year to $141.4 million. The GAAP net income rose to a record $23.9 million quarterly. While the free cash flow was also great with 46.2 million by the end of the quarter and $69.0 million by the year-end, up 132%. The prospects are strong for Glu Mobile (GLUU) as the acquisition is forthcoming.

  • Zomedica Corp.’s (ZOM) stock soars due to positive announcement

    Zomedica Corp.’s (ZOM) stock soars due to positive announcement

    Zomedica Corp.’s (NYSE: ZOM) stock has soared by 8.73% to the current value of $2.49.  In the after-hours market, the ZOM stock rose by %10.84.

    One of the major news that comes adjacent to the positive movement in the ZOM stock is its ability to sell its first commercial unit of the unique and valuable diagnostic tool kit. This tool kit was delivered to the veterinary market slightly ahead of the announced schedule.

    About Zomedica Corp

    ZomedicaCorp (NYSE American: ZOM) is a veterinary health company that creates commercial products for pets, specifically cats and dogs. They focus primarily on delivering and innovating products that tend to be the clinical veterinarians’ unmet needs. Market and business-wise, this is a brilliant tactic in which the Corp. stays ahead of the competition with its differentiated products that have more probability of being recommended by the clinical veterinarians.

    TRUFORMA delivered before its announced sale date

    The kit that has been tailor-made and sold is known as TRUFORMA, which was delivered ahead of the announced 30th March date. What this instrument does is that it is an on-site canine eACTHessay that is created to eliminate the risk of sample transport error. Furthermore, it aids in the diagnosis of adrenal disease.

    TRUFORMA was made true thanks to the collaboration of the employees at ZOM and a team of scientists/researchers at the Qorvo Biotechnologies LLC that worked as a development partner. Qorvo Biotechnologies, with the help of their special Bulk Acoustic Wave (BAW) radio frequency (RF) technology, can disrupt the veterinarian market with this innovative milestone in the form of veterinarian diagnostic.

    TRUFORMA sold to an established veterinary hospital

    The first official purchaser of the veterinarian diagnostic system-TRUFORMA is Jason Berg, DVM (Doctor of Veterinary Medicine), DACVIM (Diplomate, American College of Veterinary Internal Medicine). This is again a very clever marketing tactic because Jason Berg is the president and founder of Guardian Veterinary Specialists, an emergency critical care hospital located in New York. Dr. Berg is recognized professionally for his work as a veterinary internist and neurologist. Furthermore, Dr. Berg is a lecturer and a researcher who published several articles and professional journals that American Veterinary Medical Association has reviewed.

    What makes TRUFORMA so unique?

    Apart from this eACTH cortisol assay, there are two more out of the five initial assays available for commercial selling ahead of their time. T4 and endogenous ACTH are expected to be available soon while TSH, cortisol, and total T4 being commercially ready.

    This news is good for the ZOM stock’s positive movement because, in the field of clinical veterinary, vets have to depend on serum cortisol measurements to cater to adrenal diseases in dogs. With TRUFORMA’s enhanced efficacy and accuracy in cortisol assay, what is essentially going to revolutionize is how veterinarians will treat life-threatening adrenal diseases and give comforting news to the owners of the pets.

  • What changed for these 49 stocks in Pre Market Session

    What changed for these 49 stocks in Pre Market Session

    Lizhi Inc. (LIZI) stock plunged -8.14% to $4.4 in the pre-market trading after reporting that it entered in-car audio collaboration with Xpeng Motors. The most recent rating by Citigroup, on February 18, 2020, is a Buy.
    American Airlines Group Inc. (NASDAQ: AAL) shares are trading up 4.72% at $16.85 at the time of writing. Company’s 52-week ranged between $8.25 to $30.78.
    FuelCell Energy Inc. (FCEL) is up more than 5.01% at $7.75 in pre-market hours Friday December 04, 2020. The firm recently declared the pricing of its underwritten public offering of 34,518,539 shares of its common stock, at a public offering price of $6.50 per share. The stock had jumped over 1.93% to $7.38 in the last trading session.
    Before the trading started on December 04, 2020, AMC Entertainment Holdings Inc. (AMC) is up 5.51% to reach $3.83. It has been trading in a 52-week range of $1.95 to $8.78.
    Cinemark Holdings Inc. (CNK) stock soared 6.02% to $14.1 in the pre-market trading. The most recent rating by Loop Capital, on November 19, 2020, is a Hold.
    Iterum Therapeutics plc (ITRM), a Biotechnology company, dropped about -3.8% at $0.809 in pre-market trading Friday.
    Norwegian Cruise Line Holdings Ltd. (NYSE: NCLH) shares are trading up 3.7% at $26.36 at the time of writing following its announcement extension of suspension of voyages. Company’s 52-week ranged between $7.03 to $59.78. Analysts have a consensus price target of $26.
    Before the trading started on December 04, 2020, Jaguar Health Inc. (JAGX) is up 7.84% to reach $0.399. It has been trading in a 52-week range of $0.19 to $1.08.
    Transocean Ltd. (RIG), a Oil & Gas Drilling company, rose about 4.43% at $2.12 in pre-market trading Friday after declaring amendments to certain financing documents and internal reorganization transactions to resolve allegations contained in purported notices of default.
    Novan Inc. (NOVN) stock soared 19.92% to $0.67 in the pre-market trading. The most recent rating by Piper Jaffray, on January 06, 2020, is a Neutral.
    Li Auto Inc. (LI) lost over -2.48% at $31.51 in pre-market trading Friday December 04, 2020 following declaration its pricing of follow-on public offering of American depositary shares.
    Southwestern Energy Company (NYSE: SWN) shares are trading up 2.13% at $2.88 at the time of writing. Company’s 52-week ranged between $1.06 to $3.90. Analysts have a consensus price target of $2.40.
    Occidental Petroleum (OXY) is up more than 3.23% at $16.92 in pre-market hours Friday December 04, 2020. The company recently reported the release of its 2020 Climate Report, which provides a pathway detailing milestones to achieve its net-zero aspirations. The stock had jumped over 3.15% to $16.39 in the last trading session.
    Torchlight Energy Resources Inc. (TRCH) is up more than 6.9% at $0.48 in pre-market hours Friday December 04, 2020. The stock had jumped over 15.13% to $0.45 in the last trading session.
    TransGlobe Energy (TGA) grew over 2.82% at $0.659 in pre-market trading today following its agreement to merge, extend and modernize its eastern Desert concessions.
    Before the trading started on December 04, 2020, Catabasis Pharmaceuticals Inc. (CATB) is up 2.07% to reach $1.97. It has been trading in a 52-week range of $1.25 to $8.59.
    Inovio Pharmaceuticals Inc. (INO) stock moved up 8.07 percent to $13.53 in the pre-market trading after declaring the execution of an agreement with Kaneka Eurogentec S.A., for Eurogentec to manufacture INOVIO’s COVID-19 vaccine candidate INO-4800 at their industry-leading GMP plasmid production scales.
    Clovis Oncology Inc. (CLVS) is down more than -4.81% at $5.15 in pre-market hours Friday December 04, 2020. The stock had jumped over 11.09% to $5.41 in the last trading session.
    Cinedigm Corp. (CIDM) gained over 71.43% at $0.96 in pre-market trading Friday December 04, 2020 after reporting that its eight additional linear streaming channels are now Available on Rad’s fast-growing global streaming platform.
    Onconova Therapeutics Inc. (ONTX) stock plunged -1.9% to $0.3143 in the pre-market trading. The most recent rating by H.C. Wainwright, on March 01, 2018, is a Buy.
    Marvell Technology Group Ltd. (MRVL) stock plunged -5.1% to $43.2 in the pre-market trading after announcing a quarterly dividend of $0.06 per share of common stock payable on January 14, 2021 to shareholders of record as of December 23, 2020. The most recent rating by Craig Hallum, on October 30, 2020, is a Buy.
    QEP Resources Inc. (QEP) stock soared 5.0% to $2.1 in the pre-market trading. The most recent rating by JP Morgan, on July 20, 2020, is a Neutral.
    Arlo Technologies Inc. (NYSE: ARLO) shares are trading up 3.09% at $7.0 at the time of writing. The company recently revealed that Matthew McRae, CEO, and Gordon Mattingly, CFO, will present at the Raymond James Virtual Technology Investors Conference on Tuesday, December 8, 2020. Company’s 52-week ranged between $1.20 to $7.75. Analysts have a consensus price target of $6.
    Before the trading started on December 04, 2020, Nxt-ID Inc. (NXTD) is down -3.91% to reach $0.41. It has been trading in a 52-week range of $0.21 to $0.89.
    Halliburton Company (HAL) gained over 3.66% at $18.68 in pre-market trading Friday December 04, 2020 following its deal with Accenture (ACN), to accelerate Halliburton’s digital supply chain transformation and support digitalization within the Company’s manufacturing function.
    United Microelectronics (UMC) stock soared 10.32% to $8.55 in the pre-market trading. The most recent rating by Credit Suisse, on October 12, 2020, is an Outperform.
    Before the trading started on December 04, 2020, Cloudera Inc. (CLDR) is up 14.85% to reach $13.3 after reporting results for its third quarter of fiscal 2021, ended October 31, 2020. It has been trading in a 52-week range of $4.76 to $14.20.
    Before the trading started on December 04, 2020, Isoray Inc. (ISR) is down -4.92% to reach $0.47. It has been trading in a 52-week range of $0.35 to $1.06.
    iBio Inc. (AMEX: IBIO) shares are trading down -0.66% at $1.51 at the time of writing. The firm recently reported an agreement with Belgium-based ATB Therapeutics to produce its bioengineered antibody-toxin fusion proteins using iBio’s FastPharming® System. Company’s 52-week ranged between $0.14 to $7.45. Analysts have a consensus price target of $2.55.
    Centennial Resource Development Inc. (CDEV) stock soared 3.13% to $1.32 in the pre-market trading. The most recent rating by MKM Partners, on November 30, 2020, is a Neutral.
    BioCryst Pharmaceuticals Inc. (BCRX) is up more than 24.44% at $6.39 in pre-market hours Friday December 04, 2020 following the FDA Approval of ORLADEYO™ (berotralstat), First Oral, Once-daily Therapy to prevent attacks in Hereditary Angioedema patients. The stock had jumped over 1.88% to $5.14 in the last trading session.
    Borr Drilling Limited (BORR) is up more than 6.86% at $0.854 in pre-market hours Friday December 04, 2020. The stock had dropped over -1.78% to $0.80 in the last trading session.
    Before the trading started on December 04, 2020, Blink Charging Co. (BLNK) is up 4.14% to reach $23.64 after declaring an agreement with JSC Management Group, a large Burger King franchisee, to deploy numerous EV charging stations at key Burger King locations across the Northeast. It has been trading in a 52-week range of $1.25 to $34.67.
    Banco Santander S.A. (SAN) grew over 3.74% at $3.33 in pre-market trading today.
    Kandi Technologies Group Inc. (NASDAQ: KNDI) shares are trading up 2.98% at $8.3 at the time of writing. Company’s 52-week ranged between $2.17 to $17.45.
    InVivo Therapeutics Holdings Corp. (NVIV) lost over -4.67% at $0.6101 in pre-market trading Friday December 04, 2020.
    Aehr Test Systems (AEHR), a Semiconductor Equipment & Materials company, dropped about -8.74% at $1.88 in pre-market trading Friday after receiving $4.3 million order for initial FOX-XP™ test cell for production test of mobile sensor devices.
    ICICI Bank Limited (IBN) grew over 4.48% at $13.75 in pre-market trading today.
    NanoVibronix Inc. (NAOV) stock moved down -7.96 percent to $1.04 in the pre-market trading following the announcement of $6.0 million private placement.
    DocuSign Inc. (DOCU), a Software – Application company, rose about 4.43% at $241.25 in pre-market trading Friday.
    Dada Nexus Limited (DADA) is up more than 4.4% at $47.2 in pre-market hours Friday December 04, 2020 after reporting that Dada Now has partnered with dozens of cake chain brands across China, doubling the number of cooperating stores year-over-year as of November 2020. The stock had dropped over -15.65% to $45.21 in the last trading session.
    Salarius Pharmaceuticals Inc. (SLRX) stock moved up 1.85 percent to $1.1 in the pre-market trading.
    Auris Medical Holding Ltd. (NASDAQ: EARS) shares are trading down -3.23% at $3.3 at the time of writing after it pricing $8,000,000 common shares offering priced at-the-market. Company’s 52-week ranged between $0.65 to $6.60. Analysts have a consensus price target of $2.50.
    Acasti Pharma Inc. (ACST) lost over -2.94% at $0.33 in pre-market trading Friday December 04, 2020.
    Micro Focus International plc (MFGP) is up more than 6.3% at $6.07 in pre-market hours Friday December 04, 2020. The firm recently declared the findings of its ‘Endless Modernization’ research with Standish Group. The stock had jumped over 14.66% to $5.71 in the last trading session.
    BP p.l.c. (BP), a Oil & Gas Integrated company, rose about 4.54% at $22.33 in pre-market trading Friday.
    Tantech Holdings Ltd (NASDAQ: TANH) shares are trading up 4.27% at $1.71 at the time of writing after announcing the launch by its subsidiary, Shangchi Automobile Co., Ltd. (“Shangchi Automobile”), of its newest highly innovative driverless and autonomous street sweeper. Company’s 52-week ranged between $0.81 to $3.65.
    Trine Acquisition Corp. (TRNE) gained over 7.05% at $15.49 in pre-market trading Friday December 04, 2020.
    Enlivex Therapeutics Ltd. (ENLV) grew over 5.26% at $12.0 in pre-market trading today after reporting positive interim results of an investigator-initiated Phase II clinical trial evaluating AllocetraTM in severe and critical COVID-19 patients.

  • 49 Stocks Making Sharp Moves in Pre Market Session

    49 Stocks Making Sharp Moves in Pre Market Session

    BlackBerry Limited (BB) stock soared 21.29% to $8.49 in the pre-market trading following the announcement of its multi-year, global agreement with Amazon Web Services, Inc. (AWS). The most recent rating by TD Securities, on April 01, 2020, is a Hold.
    Gores Metropoulos Inc. (GMHI), a Shell Companies company, dropped about -3.71% at $16.37 in pre-market trading Wednesday.
    Carnival Corporation & Plc (NYSE: CCL) shares are trading up 2.48% at $20.65 at the time of writing. The firm recently reported Peter C. Anderson as a Section 16 Named Executive Officer. Company’s 52-week ranged between $7.80 to $51.94. Analysts have a consensus price target of $31.
    Guardion Health Sciences Inc. (GHSI) is up more than 2.11% at $0.3 in pre-market hours Wednesday December 02, 2020. The stock had jumped over 11.71% to $0.29 in the last trading session.
    Advaxis Inc. (ADXS) grew over 0.85% at $0.32 in pre-market trading today. The healthcare company recently announced closing of $9.2 million public offering.
    Before the trading started on December 02, 2020, RiceBran Technologies (RIBT) is down -5.56% to reach $0.68. It has been trading in a 52-week range of $0.37 to $2.43.
    Sundial Growers Inc. (SNDL) stock moved up 5.75 percent to $0.69 in the pre-market trading and the company recently announced elimination of senior secured second lien convertible notes.
    Kaixin Auto Holdings (KXIN) is up more than 4.55% at $7.35 in pre-market hours Wednesday December 02, 2020. The stock had jumped over 8.32% to $7.03 in the last trading session.
    Moleculin Biotech Inc. (MBRX) lost over -7.83% at $0.9125 in pre-market trading Wednesday December 02, 2020 after declaring that the US Food and Drug Administration (FDA) has approved its request for a “Rare Pediatric Disease” designation for its drug candidate WP1066.
    Jaguar Health Inc. (JAGX) stock plunged -5.83% to $0.4313 in the pre-market trading. The most recent rating by Rodman & Renshaw, on July 11, 2017, is a Buy.
    Auris Medical Holding Ltd. (EARS) stock plunged -17.97% to $4.29 in the pre-market trading after reporting positive efficacy data from testing AM-301 in vitro. The most recent rating by Euro Pacific Capital, on October 08, 2018, is a Buy.
    Before the trading started on December 02, 2020, Sunworks Inc. (SUNW) is up 9.88% to reach $4.67. It has been trading in a 52-week range of $0.29 to $8.50.
    China Automotive Systems Inc. (NASDAQ: CAAS) shares are trading down -4.95% at $8.25 at the time of writing after the firm declared that its shipped approximately 120,000 units from its portfolio of electric power steering products for use in Chinese electric vehicles during 2020. Company’s 52-week ranged between $1.42 to $10.50.
    Tilray Inc. (NASDAQ: TLRY) shares are trading up 1.61% at $8.2 at the time of writing. Company’s 52-week ranged between $2.43 to $22.95. Analysts have a consensus price target of $4.77.
    Ocugen Inc. (OCGN) lost over -8.87% at $0.3101 in pre-market trading Wednesday December 02, 2020. The company recently reported that leading independent proxy firms ISS and Glass Lewis recommended Ocugen stockholders vote “FOR” reverse stock split and authorized shares amendment proposals.
    AMC Entertainment Holdings Inc. (AMC) is up more than 2.41% at $4.25 in pre-market hours Wednesday December 02, 2020. The stock had dropped over -2.81% to $4.15 in the last trading session.
    Before the trading started on December 02, 2020, JetBlue Airways Corporation (JBLU) is down -4.67% to reach $14.7 following the declaration of its pricing of common stock offering. It has been trading in a 52-week range of $6.61 to $21.65.
    Before the trading started on December 02, 2020, Uxin Limited (UXIN) is down -3.65% to reach $1.32. It has been trading in a 52-week range of $0.72 to $3.10.
    Li Auto Inc. (NASDAQ: LI) shares are trading up 1.78% at $35.48 at the time of writing after announcing that the Company delivered 4,646 Li ONEs in November 2020. Company’s 52-week ranged between $14.31 to $47.70. Analysts have a consensus price target of $45.60.
    Aurora Cannabis Inc. (ACB) stock soared 3.59% to $10.1 in the pre-market trading. The most recent rating by Jefferies, on November 16, 2020, is an Underperform.
    Tantech Holdings Ltd (TANH), a Household & Personal Products company, dropped about -3.24% at $1.79 in pre-market trading Wednesday after reporting the launch by its subsidiary, Shangchi Automobile Co., Ltd., of its newest highly innovative driverless and autonomous street sweeper.
    Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP) shares are trading down -5.52% at $1.37 at the time of writing. Company’s 52-week ranged between $0.91 to $9.78. Analysts have a consensus price target of $3.
    iBio Inc. (IBIO) is up more than 19.31% at $1.73 in pre-market hours Wednesday December 02, 2020 after revealing that it has entered into its first Statement of Work (“SoW”) under a Master Services Agreement with ATB Therapeutics to produce its bioengineered antibody-toxin fusion proteins using iBio’s FastPharming® System. The stock had dropped over -2.68% to $1.45 in the last trading session.
    Norwegian Cruise Line Holdings Ltd. (NYSE: NCLH) shares are trading up 2.09% at $23.42 at the time of writing. Company’s 52-week ranged between $7.03 to $59.78. Analysts have a consensus price target of $26.
    Moderna Inc. (MRNA) stock soared 6.09% to $149.6 in the pre-market trading. The biotechnology firm reported recently, that the primary efficacy analysis of the Phase 3 study of mRNA-1273 conducted on 196 cases confirms the high efficacy observed at the first interim analysis. The most recent rating by Wells Fargo, on November 23, 2020, is an Equal weight.
    Switchback Energy Acquisition Corporation (SBE) is down more than -4.16% at $28.13 in pre-market hours Wednesday December 02, 2020. The stock had dropped over -12.67% to $29.35 in the last trading session.
    Novavax Inc. (NVAX) grew over 4.84% at $129.44 in pre-market trading today after declaring COVID-19 vaccine clinical development progress.
    Before the trading started on December 02, 2020, Eastman Kodak Company (KODK) is up 3.88% to reach $7.5. It has been trading in a 52-week range of $1.50 to $60.00.
    ReneSola Ltd (SOL), a Solar company, dropped about -11.66% at $6.97 in pre-market trading Wednesday after releasing its third quarter 2020 financial results.
    Acasti Pharma Inc. (ACST) stock plunged -9.56% to $0.3301 in the pre-market trading. The most recent rating by Oppenheimer, on September 01, 2020, is a Perform.
    Pfizer Inc. (PFE) stock moved up 3.73 percent to $40.88 in the pre-market trading after the firm and BioNTech SE reporting that the Medicines & Healthcare Products Regulatory Agency (MHRA) in the U.K. has granted a temporary authorization for emergency use for their COVID-19 mRNA vaccine (BNT162b2), against COVID-19.
    Gevo Inc. (NASDAQ: GEVO) shares are trading down -3.17% at $1.83 at the time of writing. Company’s 52-week ranged between $0.46 to $2.91.
    Fisker Inc. (FSR) is down more than -3.41% at $17.55 in pre-market hours Wednesday December 02, 2020. The company recently reported that that Henrik Fisker, chairman and chief executive officer of Fisker, will participate in the Credit Suisse Eighth Annual Virtual Industrials Conference. The stock had dropped over -6.24% to $18.17 in the last trading session.
    Nxt-ID Inc. (NXTD) grew over 43.17% at $0.587 in pre-market trading today.
    Before the trading started on December 02, 2020, Bloom Energy Corporation (BE) is down -6.58% to reach $23.0 and the company will host virtual analyst day on December 16, 2020. It has been trading in a 52-week range of $3.00 to $28.24.
    Ocean Power Technologies Inc. (OPTT), a Electrical Equipment & Parts company, dropped about -3.54% at $2.45 in pre-market trading Wednesday.
    Nikola Corporation (NKLA) stock soared 4.38% to $18.13 in the pre-market trading after signing MOU with General Motors. The most recent rating by Loop Capital, on November 20, 2020, is a Buy.
    Vaxart Inc. (VXRT) gained over 3.92% at $7.95 in pre-market trading Wednesday December 02, 2020.
    salesforce.com inc. (CRM) lost over -4.16% at $231.3 in pre-market trading Wednesday December 02, 2020 after introducing service cloud workforce engagement to help contact centers thrive in an all-digital, work-from-anywhere world.
    InVivo Therapeutics Holdings Corp. (NVIV), a Biotechnology company, rose about 2.42% at $0.635 in pre-market trading Wednesday.
    FuelCell Energy Inc. (FCEL) stock plunged -20.11% to $7.23 in the pre-market trading following the publication pricing of its underwritten public offering of 34,518,539 shares of its common stock, at a public offering price of $6.50 per share. The most recent rating by JP Morgan, on November 19, 2020, is a Neutral.
    Pershing Square Tontine Holdings Ltd. (PSTH), a Shell Companies company, rose about 2.34% at $26.25 in pre-market trading Wednesday.
    Virgin Galactic Holdings Inc. (NYSE: SPCE) shares are trading up 4.37% at $29.59 at the time of writing after reporting its new flight window since it paused the spaceflight preparations in response to state guidelines from the New Mexico Department of Health to reduce the spread of COVID-19. Company’s 52-week ranged between $7.14 to $42.49. Analysts have a consensus price target of $19.
    Second Sight Medical Products Inc. (EYES) stock moved down -8.0 percent to $1.38 in the pre-market trading.
    BioNTech SE (BNTX) grew over 7.36% at $122.4 in pre-market trading today after declaring that it will hold a press conference including a video webcast on Wednesday, December 2, 2020, to provide an update on the status of the COVID-19 vaccine development program of its lead vaccine candidate BNT162b2.
    Sogou Inc. (SOGO), a Internet Content & Information company, rose about 3.09% at $8.68 in pre-market trading Wednesday.
    Tellurian Inc. (TELL) is down more than -4.29% at $1.56 in pre-market hours Wednesday December 02, 2020 and the firm recently declared the appointment veteran CEO and adds industry experts to board of directors. The stock had jumped over 9.40% to $1.63 in the last trading session.
    Arlo Technologies Inc. (ARLO) lost over -3.48% at $6.66 in pre-market trading Wednesday December 02, 2020.
    Before the trading started on December 02, 2020, ZoomInfo Technologies Inc. (ZI) is down -3.57% to reach $46.22 as the firm announced pricing of secondary offering of shares of class a common stock. It has been trading in a 52-week range of $30.83 to $64.40.

  • ZomedicaCorp. (ZOM) shares spiked in the after-market session

    ZomedicaCorp. (NYSE: ZOM) stock jumped 14.46% to 0.205 in the after-market session. Yet, there does notseem to be any company-specific news that has prompted Ideanomics’ share priceto increase today, and investors will want to take that as a warning sign.

    Nevertheless, on November 12, 2020, the firm with the marketcapitalization of 101.02M officially posted consolidated financial reports for the thirdquarter ended September 30, 2020.

    Zomedica(NYSE: ZOM) revealed that Research and development spending for the quarter

    ended September 30, 2020, was about $2.7 million, compared to approximately $1.0million for the three months ended September 30, 2019, a rise of approximately1.7 million, or 181percent. The rise was largely attributed to a milestonecost of $2.0 million under ourproduction and supply dealwith QorvoBiotechnologies, LLC., compensated in part by reducing about $237,000 in agreedexpenditures, materials, regulatory fees, and consultancy fees.

    Moreover,a veterinary health organization developing point-of-care testing products fordogs and cats revealed on November 13, 2020, a plan to deliver the TRUFORMAa point-of-care  diagnostic platform on March 30, 2021.